A PACAP receptor antagonist
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

PACAP (6-38) (human, chicken, mouse, ovine, porcine, rat) (trifluoroacetate salt)

Item No. 24554

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
L-phenylalanyl-L-threonyl-L-α-aspartyl-L-seryl-L-tyrosyl-L-seryl-L-arginyl-L-tyrosyl-L-arginyl-L-lysyl-L-glutaminyl-L-methionyl-L-alanyl-L-valyl-L-lysyl-L-lysyl-L-tyrosyl-L-leucyl-L-alanyl-L-alanyl-L-valyl-L-leucylglycyl-L-lysyl-L-arginyl-L-tyrosyl-L-lysyl-L-glutaminyl-L-arginyl-L-valyl-L-lysyl-L-asparaginyl-L-lysinamide, trifluoroacetate salt
Synonyms
  • Pituitary Adenylate Cyclase-activating Peptide (6-38)
Molecular Formula
C182H300N56O45S • XCF3COOH
Formula Weight
4024.7
Purity
≥95%
Formulation (Request formulation change)
A lyophilized powder
Solubility(Learn about Variance in Solubility)
Water: 1 mg/ml
SMILES
NC([C@H](CCCCN)NC([C@H](CC(N)=O)NC([C@H](CCCCN)NC([C@H](C(C)C)NC([C@H](CCCNC(N)=N)NC([C@H](CCC(N)=O)NC([C@H](CCCCN)NC([C@@H](NC([C@H](CCCNC(N)=N)NC([C@H](CCCCN)NC(CNC([C@H](CC(C)C)NC([C@H](C(C)C)NC([C@@H](NC([C@@H](NC([C@H](CC(C)C)NC([C@@H](NC([C@H](CCCCN)NC([C@H](CCCCN)NC([C@H](C(C)C)NC([C@@H](NC([C@@H](NC([C@H](CCC(N)=O)NC([C@H](CCCCN)NC([C@H](CCCNC(N)=N)NC([C@@H](NC([C@H](CCCNC(N)=N)NC([C@H](CO)NC([C@@H](NC([C@H](CO)NC([C@@H](NC([C@@]([C@@H](C)O)([H])NC([C@@H](N[H])CC1=CC=CC=C1)=O)=O)CC(O)=O)=O)=O)CC2=CC=C(O)C=C2)=O)=O)=O)CC3=CC=C(O)C=C3)=O)=O)=O)=O)CCSC)=O)C)=O)=O)=O)=O)CC4=CC=C(O)C=C4)=O)=O)C)=O)C)=O)=O)=O)=O)=O)=O)CC5=CC=C(O)C=C5)=O)=O)=O)=O)=O)=O)=O)=O.FC(F)(C(O)=O)F
InChi Code
InChI=1S/C182H300N56O45S.C2HF3O2/c1-95(2)83-128(152(257)207-92-141(249)211-115(40-20-27-72-184)154(259)215-122(47-34-79-204-180(197)198)161(266)226-130(86-105-50-58-109(242)59-51-105)167(272)217-117(42-22-29-74-186)156(261)220-125(66-68-138(191)246)163(268)216-124(49-36-81-206-182(201)202)165(270)237-145(99(9)10)176(281)224-120(45-25-32-77-189)160(265)230-134(90-140(193)248)171(276)212-114(147(194)252)39-19-26-71-183)231-177(282)144(98(7)8)236-149(254)101(12)208-148(253)100(11)210-166(271)129(84-96(3)4)225-169(274)132(88-107-54-62-111(244)63-55-107)228-159(264)118(43-23-30-75-187)214-157(262)119(44-24-31-76-188)223-175(280)143(97(5)6)235-150(255)102(13)209-153(258)127(70-82-284-15)222-164(269)126(67-69-139(192)247)221-155(260)116(41-21-28-73-185)213-158(263)121(46-33-78-203-179(195)196)218-168(273)131(87-106-52-60-110(243)61-53-106)227-162(267)123(48-35-80-205-181(199)200)219-173(278)136(93-239)233-170(275)133(89-108-56-64-112(245)65-57-108)229-174(279)137(94-240)234-172(277)135(91-142(250)251)232-178(283)146(103(14)241)238-151(256)113(190)85-104-37-17-16-18-38-104;3-2(4,5)1(6)7/h16-18,37-38,50-65,95-103,113-137,143-146,239-245H,19-36,39-49,66-94,183-190H2,1-15H3,(H2,191,246)(H2,192,247)(H2,193,248)(H2,194,252)(H,207,257)(H,208,253)(H,209,258)(H,210,271)(H,211,249)(H,212,276)(H,213,263)(H,214,262)(H,215,259)(H,216,268)(H,217,272)(H,218,273)(H,219,278)(H,220,261)(H,221,260)(H,222,269)(H,223,280)(H,224,281)(H,225,274)(H,226,266)(H,227,267)(H,228,264)(H,229,279)(H,230,265)(H,231,282)(H,232,283)(H,233,275)(H,234,277)(H,235,255)(H,236,254)(H,237,270)(H,238,256)(H,250,251)(H4,195,196,203)(H4,197,198,204)(H4,199,200,205)(H4,201,202,206);(H,6,7)/t100-,101-,102-,103+,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,127-,128-,129-,130-,131-,132-,133-,134-,135-,136-,137-,143-,144-,145-,146-;/m0./s1
InChi Key
VUTZKHJLSOPDFM-IKLXZCEOSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    500 µg

    $255

    Add

    1 mg

    $480

    Add
    Cayman Chemical
    Visit Our Cancer Resource Center
    Find Tools & Resources to Study the Hallmarks of Cancer
    • Cancer cell signaling & regulation
    • Cancer metabolism
    • Tumor microenvironment
    EXPLORE NOW
    Product Description

    Pituitary adenylate cyclase-activating peptide (PACAP) (6-38) is a PACAP receptor antagonist with IC50 values of 30, 600, and 40 nM, respectively for rat PAC1, rat VPAC1, and human VPAC2 recombinant receptors expressed in CHO cells.1 It binds to PACAP receptors in rat brain membrane (IC50 = 39.14 nM) and to SH-SY5Y and SK-N-MC human neuroblastoma and T47D human breast cancer cells (IC50s = 2.9, 129, and 227 nM, respectively).2,3 In vivo, in newborn pigs, PACAP (6-38) (10 μM) inhibits vasodilation of pial arterioles induced by PACAP (1-38) (Item No. 24770), the full-length peptide.4 It also inhibits decreased food intake and reduced body weight in rats induced by cocaine- and amphetamine-regulated transcript peptides (CARTp) following intracerebroventricular administration of 0.3-3 mol per animal doses.5

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Gourlet, P., Vandermeers, A., Vandermeers-Piret, M.-C., et al. Fragments of pituitary adenylate cyclase activating polypeptide discriminate between type I and II recombinant receptors. Eur. J. Pharmacol. 287(1), 7-11 (1995).

    2. Moro, O., Wakita, K., Ohnuma, M., et al. Functional characterization of structural alterations in the sequence of the vasodilatory peptide maxadilan yields a pituitary adenylate cyclase-activating peptide type 1 receptor-specific antagonist. The Journal of Biological Chemisty 274(33), 23103-23110 (1999).

    3. Eggenberger, M., Born, W., Zimmermann, U., et al. Maxadilan interacts with receptors for pituitary adenylyl cyclase activating peptide in human SH-SY5Y and SK-N-MC neuroblastoma cells. Neuropeptides 33(2), 107-114 (1999).

    4. Lenti, L., Domoki, F., Kis, D., et al. Pituitary adenylate cyclase-activating polypeptide induces pial arteriolar vasodilation through cyclooxygenase-dependent and independent mechanisms in newborn pigs. Brain Res. 1165, 81-88 (2007).

    5. Burgos, J.R., Iresjö, B.-M., and Smedh, U. Pituitary adenylate cyclase-activating polypeptide 6-38 blocks cocaine- and amphetamine-regulated transcript Peptide-induced hypophagia in rats. PLoS One 8(8):e72347, (2013).